Leukemia Clinical Trials

Showing 3621-3640 of 5,235 trials

UNKNOWN

Increase Surveillance for Wellness Decisions, Also to Determine Targeted Risk-reducing and Preventative Strategies

NCT03322241

Healthcare Decisions Post-Testing On Risk Reducing, and Preventative Strategies Utilizing Wellness Lab Tests

Overall Wellness

Data Collection Analysis Business Management200 participantsStarted May 2017

Land O' Lakes, Florida, United States

TERMINATEDPhase 2

GRN1005 in Non-Small Cell Lung Cancer (NSCLC) Patients With Brain Metastases (GRABM-L)

NCT01497665

The purpose of this study is to assess the efficacy, safety, and tolerability of GRN1005 in patients with brain metastases from non-small cell lung cancer (NSCLC).

Non-small Cell Lung Cancer (NSCLC) With Brain Metastases

Angiochem Inc16 participantsStarted Nov 2011

La Jolla, California, United States • Aurora, Colorado, United States • Tampa, Florida, United States +7 more locations

TERMINATEDPhase 3

SHR1020 Plus Docetaxel as Compared to Placebo Plus Docetaxel in 2nd Line Non Squamous Non Small Cell Lung Cancer

NCT02766140

The present trial will be performed to evaluate whether SHR1020 in combination with docetaxel in patients with Local Advanced or Metastatic or recurrent Non Squamous NSCLC is more effective as compared to placebo in combination with docetaxel. A secondary aim is to obtain safety information as well as information on quality of life of patients treated with SHR1020 in combination with docetaxel.

Non Squamous Non Small Cell Lung

Jiangsu HengRui Medicine Co., Ltd.12 participantsStarted Jun 2016

Shanghai, Shanghai Municipality, China

Increase Surveillance for Wellness Decisions, Also to Determine Targeted Risk-reducing and Preventative Strategies

GRN1005 in Non-Small Cell Lung Cancer (NSCLC) Patients With Brain Metastases (GRABM-L)

SHR1020 Plus Docetaxel as Compared to Placebo Plus Docetaxel in 2nd Line Non Squamous Non Small Cell Lung Cancer

Related Searches

Heart Failure After Heart Transplantation Due to Chronic Rejection

Efficacy and Safety of SCT200 in Patients With Advanced Squamous Non-small Cell Lung Cancer

A Study to Assess the Efficacy of Rituximab (MabThera) in First Line Treatment of Chronic Lymphocytic Leukemia (CLL)

Short Course Radiation Therapy in Palliative Treatment of Pelvic Cancer

Consolidation Therapy With Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19 in Patients With Chronic Lymphocytic Leukemia Following Upfront Chemotherapy With Pentostatin, Cyclophosphamide and Rituximab

Mechanical Ventilation Practices in Uganda's Intensive Care Units

Azacitidine Plus Phenylbutyrate in Treating Patients With Advanced or Metastatic Solid Tumors That Have Not Responded to Previous Treatment

Observational Study of the Safety and Efficacy of Norditropin® in Patients With SGA (Small for Gestational Age) Short Stature That Are Still Growing

Study Of Dacomitinib (PF-00299804) In Advanced NSCLC Patients (Post Chemo Or Select First Line) To Evaluate Prophylactic Intervention On Derm And GI AEs And PRO

Clinicopathological Features of NSCLC Patients Associated With the Chromosome 2p (EML4-ALK)

Pioglitazone and Tyrosine Kinase Inhibitor in Treating Patients With Relapsed Chronic Myeloid Leukemia

Use of Honey for Pressure Ulcers in Critically Ill Children

Study of Tarceva and Targretin in Stage I-II Lung Cancer

Dacomitinib (PF-00299804) As A Single Oral Agent In Selected Patients With Adenocarcinoma Of The Lung

A Study of Atezolizumab in Participants With Programmed Death-Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) [FIR]

Everolimus and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Hematologic Cancer

A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Solid Tumors